Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer

Highlights • Subtypes of KRAS mutated NSCLC may respond differently to chemotherapy treatment. • Indeed, patients with G12V mutation had an improved response to taxanes. • Patients with G12C/G12D mutation had comparable outcome in all chemotherapy regimen. • Carboplatin/bevacizumab/taxanes had highe...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-11, Vol.90 (2), p.249-254
Main Authors: Mellema, Wouter W, Masen-Poos, Lucie, Smit, Egbert F, Hendriks, Lizza E.L, Aerts, Joachim G, Termeer, Arien, Goosens, Martijn J, Smit, Hans J.M, van den Heuvel, Michel M, van der Wekken, Anthonie J, Herder, Gerarda J.M, Krouwels, Frans H, Stigt, Jos A, van den Borne, Ben E.E.M, Haitjema, Tjeerd J, Staal-Van den Brekel, Agnes J, van Heemst, Robbert C, Pouw, Ellen, Dingemans, Anne-Marie C
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Chemotherapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Disease-Free Survival
Female
Guanine - administration & dosage
Hematology, Oncology and Palliative Medicine
Humans
KRAS mutation
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
Mutation - drug effects
Mutation - genetics
Non-small cell lung cancer
Organoplatinum Compounds - administration & dosage
Outcome
Prognosis
Pulmonary/Respiratory
ras Proteins - genetics
Retrospective Studies
Taxoids - administration & dosage
Type of KRAS mutation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Subtypes of KRAS mutated NSCLC may respond differently to chemotherapy treatment. • Indeed, patients with G12V mutation had an improved response to taxanes. • Patients with G12C/G12D mutation had comparable outcome in all chemotherapy regimen. • Carboplatin/bevacizumab/taxanes had highest response in the unselected study group.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.09.012